Ani Pharmaceuticals, a generic pharmaceutical company, has appointed Arthur Przybyl as its new CEO. Mr Przybyl will also become a member of Ani's board of directors.
Subscribe to our email newsletter
Mr Przybyl is replacing Tom Anderson, Ani’s founding CEO, who is leaving to pursue other opportunities. Mr Anderson will remain on Ani’s board of directors.
Most recently, Mr Przybyl was the president and CEO of Akorn, a manufacturer of sterile specialty pharmaceutical products.
Charlotte Arnold, board member of Ani, said: “On behalf of the board and Ani’s investors, I am very pleased to welcome Art as the company’s new CEO. I look forward to working with him and the entire Ani team to accomplish the company’s objective of becoming a leading specialty pharmaceutical company in the generic industry.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.